Fiche publication
Date publication
décembre 2021
Journal
Scientific reports
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MONASSIER Laurent
Tous les auteurs :
Arnoux A, Ayme-Dietrich E, Dieterle S, Goy MA, Schann S, Frauli M, Monassier L, Dupuis L
Lien Pubmed
Résumé
Degeneration of brainstem serotonin neurons has been demonstrated in ALS patients and mouse models and was found responsible for the development of spasticity. Consistent with involvement of central serotonin pathways, 5-HT receptor (5-HTR) was upregulated in microglia of ALS mice. Its deletion worsened disease outcome in the Sod1 mouse model and led to microglial degeneration. In ALS patients, a polymorphism in HTR2B gene leading to higher receptor expression in CNS, was associated with increased survival in patients as well as prevention of microglial degeneration. Thus, the aim of our study was to determine the effect of a 5-HTR agonist : BW723C86 (BW), in the Sod1 mouse model. Despite good pharmacokinetic and pharmacological profiles, BW did not ameliorate disease outcome or motor neuron degeneration in a fast progressing mouse model of ALS despite evidence of modulation of microglial gene expression.
Mots clés
Amyotrophic Lateral Sclerosis, drug therapy, Animals, Disease Models, Animal, Female, Indoles, pharmacology, Male, Mice, Mice, Transgenic, Microglia, drug effects, Motor Neurons, drug effects, Nerve Degeneration, drug therapy, Receptor, Serotonin, 5-HT2B, metabolism, Serotonin, metabolism, Serotonin 5-HT2 Receptor Agonists, pharmacology, Superoxide Dismutase-1, metabolism, Thiophenes, pharmacology
Référence
Sci Rep. 2021 12 8;11(1):23582
